# Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

> **NCT06130995** · PHASE1 · RECRUITING · sponsor: **University of Oklahoma** · enrollment: 46 (estimated)

## Conditions studied

- Androgen Deprivation Therapy
- Locally Advanced Prostate Cancer

## Interventions

- **DRUG:** Relugolix and Enzalutamide

## Key facts

- **NCT ID:** NCT06130995
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-26
- **Primary completion:** 2029-01
- **Final completion:** 2030-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06130995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06130995, "Relugolix + Enzalutamide Study in High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06130995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*